User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D : A : D Study

Primary tabs

Law, MG Friis-Moller, N. El-Sadr, WM Weber, R. Reiss, P. Phillips, Andrew [UCL] Lundgren, JD.

Background The D:A:D (Data Collection on Adverse Events of Anti-HIV Drugs) Study, a prospective observational study on a cohort of 23 468 patients with HIV infection, indicated that the incidence of myocardial infarction (MI) increased by 26% per year of exposure to combination antiretroviral treatment (CART). However, it remains unclear whether the observed increase in the rate of MI in this population can be attributed to changes in conventional cardiovascular risk factors. Objective To compare the number of MIs observed among participants in the D:A:D Study with the number predicted by assuming that conventional cardiovascular risk equations apply to patients with HIV infection. Methods The Framingham equation, a conventional cardiovascular risk algorithm, was applied to individual patient data in the D:A:D Study to predict rates of MI by duration of CART. A series of sensitivity analyses were performed to assess the effect of model and data assumptions. Predictions were extrapolated to provide 10-year risk estimates, and various scenarios were modelled to assess the expected effect of different interventions. Results In patients receiving CART, the observed numbers of MIs during D:A:D follow up were similar to or somewhat higher than predicted numbers: 9 observed vs 5.5 events predicted, 14 vs 9.8, 22 vs 14.9, 31 vs 23.2 and 47 vs 37.0 for < 1 year, 1-2 years, 2-3 years, 3-4 years and > 4 years CART exposure, respectively. In patients who had not received CART, the observed number of MIs was fewer than predicted (3 observed vs 7.6 predicted). Nine per cent of the study population have a predicted 10-year risk of MI above 10%, a level usually associated with initiation of intervention on risk factors. Conclusion A consistent feature of all analyses was that observed and predicted rates of MI increased in a parallel fashion with increased CART duration, suggesting that the observed increase in risk of MI may at least in part be explained by CART-induced changes in conventional risk factors. These findings provide guidance in terms of choosing lifestyle or therapeutic interventions to decrease those risk factors in much the same way as in persons without HIV infection.

Document type Article de périodique (Journal article) – Article de recherche
Publication date 2006
Language Anglais
Journal information "HIV Medicine" - Vol. 7, no. 4, p. 218-230 (2006)
Peer reviewed yes
Publisher Blackwell Publishing (Oxford)
issn 1464-2662
e-issn 1468-1293
Publication status Publié
Affiliation UCL
Keywords antiretroviral therapy ; Framingham risk equation ; myocardial infarction
Links
  1. Carr Andrew, Samaras Katherine, Burton Samantha, Law Matthew, Freund Judith, Chisholm Donald J., Cooper David A., A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors : , 10.1097/00002030-199807000-00003
  2. Periard D., Telenti A., Sudre P., Cheseaux J.-J., Halfon P., Reymond M. J., Marcovina S. M., Glauser M. P., Nicod P., Darioli R., Mooser V., Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors, 10.1161/01.cir.100.7.700
  3. Behrens Georg, Dejam Andre, Schmidt Hartmut, Balks Hans-Joachim, Brabant Georg, Körner Thorsten, Stoll Matthias, Schmidt Reinhold E., Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors : , 10.1097/00002030-199907090-00001
  4. Noor Mustafa A., Seneviratne Tara, Aweeka Francesca T., Lo Joan C., Schwarz Jean-Marc, Mulligan Kathleen, Schambelan Morris, Grunfeld Carl, Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study : , 10.1097/00002030-200203290-00002
  5. Hadigan C., Meigs J. B., Corcoran C., Rietschel P., Piecuch S., Basgoz N., Davis B., Sax P., Stanley T., Wilson P. W. F., D'Agostino R. B., Grinspoon S., Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy, 10.1086/317541
  6. Menotti A, J Cardiovasc Risk, 3, 69 (1996)
  7. Wilson P. W. F., D'Agostino R. B., Levy D., Belanger A. M., Silbershatz H., Kannel W. B., Prediction of Coronary Heart Disease Using Risk Factor Categories, 10.1161/01.cir.97.18.1837
  8. Sytkowski PA, N Engl J Med, 322, 1635 (1990)
  9. Vittecoq D, Escaut L, Monsuez JJ, Vascular complications associated with use of HIV protease inhibitors, 10.1016/s0140-6736(05)78644-x
  10. Holmberg Scott D, Moorman Anne C, Williamson John M, Tong Tony C, Ward Douglas J, Wood Kathy C, Greenberg Alan E, Janssen Robert S, Protease inhibitors and cardiovascular outcomes in patients with HIV-1, 10.1016/s0140-6736(02)11672-2
  11. Mary-Krause Murielle, Cotte Laurent, Simon Anne, Partisani Maria, Costagliola Dominique, Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men : , 10.1097/00002030-200311210-00010
  12. Combination Antiretroviral Therapy and the Risk of Myocardial Infarction, 10.1056/nejmoa030218
  13. Klein Daniel, Hurley Leo B., Quesenberry Charles P., Sidney Stephen, Do Protease Inhibitors Increase the Risk for Coronary Heart Disease in Patients With HIV-1 Infection? : , 10.1097/00126334-200208150-00002
  14. Anderson Keaven M., Odell Patricia M., Wilson Peter W.F., Kannel William B., Cardiovascular disease risk profiles, 10.1016/0002-8703(91)90861-b
  15. Currier Judith S., Taylor Anne, Boyd Felicity, Dezii Christopher M., Kawabata Hugh, Burtcel Beth, Maa Jen-Fue, Hodder Sally, Coronary Heart Disease in HIV-Infected Individuals : , 10.1097/00126334-200308010-00012
  16. Dong KL, J Acquir Immune Defic Syndr, 21, 107 (1999)
  17. Saves M., Chene G., Ducimetiere P., Leport C., Le Moal G., Amouyel P., Arveiler D., Ruidavets J.-B., Reynes J., Bingham A., Raffi F., , Risk Factors for Coronary Heart Disease in Patients Treated for Human Immunodeficiency Virus Infection Compared with the General Population, 10.1086/375844
  18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), 10.1001/jama.285.19.2486
  19. De Backer G, European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts), 10.1016/s0195-668x(03)00347-6
  20. FAERGEMAN O., New British recommendations for prevention of coronary heart disease in clinical practice, 10.1136/hrt.81.4.335
  21. Lauer Michael S., Updated Guidelines for Cholesterol Management, 10.1001/jama.285.19.2508
  22. Ramsay LE, Wallis EJ, Haq IU, Yeo WW, Jackson PR, Drug therapy for coronary heart disease: the Sheffield table, 10.1016/s0140-6736(98)26006-5
  23. Friis-Møller Nina, Weber Rainer, Reiss Peter, Thiébaut Rodolphe, Kirk Ole, Monforte Antonella d'Arminio, Pradier Christian, Morfeldt Linda, Mateu Silvia, Law Matthew, El-Sadr Wafaa, De Wit Stephan, Sabin Caroline A, Phillips Andrew N, Lundgren Jens D, Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study : , 10.1097/00002030-200305230-00010
  24. Tunstall-Pedoe H., Kuulasmaa K., Amouyel P., Arveiler D., Rajakangas A. M., Pajak A., Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents, 10.1161/01.cir.90.1.583
  25. 25 D:A:D Coordinating Centre.Data Collection on Adverse Events of Anti-HIV Drugs; Study Documents. http://www.cphiv.dk/2004
  26. 26 WHO.MONICA Project. MONICA Manual, Part IV, Event Registration. http:/www.ktl.fi/publications/monica/manual/part4/iv-1.htm2004.
  27. Kannel William B., Abbott Robert D., Incidence and Prognosis of Unrecognized Myocardial Infarction : An Update on the Framingham Study, 10.1056/nejm198411013111802
  28. Law M, Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Calvo G, El-Sadr W, De Wit S, Sabin CA, Lundgren JD, , Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study, 10.1046/j.1468-1293.2003.00138.x
  29. Little R, Statistical Analysis with Missing Data (1987)
  30. Haffner Steven M., Lehto Seppo, Rönnemaa Tapani, Pyörälä Kalevi, Laakso Markku, Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction, 10.1056/nejm199807233390404
  31. Pekkanen J, N Engl J Med, 322, 1700 (1990)
  32. Rosengren A., Hagman M., Wedel H., Wilhelmsen L., Serum cholesterol and long-term prognosis in middle-aged men with myocardial infarction and angina pectoris: A 16-year follow-up of the Primary Prevention Study in Gateborg, Sweden, 10.1093/oxfordjournals.eurheartj.a015340
  33. 33 World Health Organisation (WHO).1997-1999 World Health Statistics Annual. http://www3.who.int/whosis/menu.cfm2004
  34. Efron Bradley, Tibshirani Robert J., An Introduction to the Bootstrap, ISBN:9780412042317, 10.1007/978-1-4899-4541-9
  35. Thomsen Troels, Davidsen Michael, Ibsen Hans, Jorgensen Torben, Jensen Gorm, Borch-Johnsen Knut, 10.1097/00043798-200110000-00008
  36. Empana J, Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study, 10.1016/j.ehj.2003.09.002
  37. De Visser C. L., Bilo H. J. G., Thomsen T. F., Groenier K. H., Meyboom-De Jong B., Prediction of coronary heart disease: a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population, 10.1046/j.1365-2796.2003.01137.x
  38. Thomsen Troels F, McGee Dan, Davidsen Michael, Jørgensen Torben, A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study, 10.1093/ije/31.4.817
  39. Tunstall-Pedoe Hugh, Kuulasmaa Kari, Mähönen Markku, Tolonen Hanna, Ruokokoski Esa, Contribution of trends in survival and coronar y-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations, 10.1016/s0140-6736(99)04021-0
  40. Koppel Kristina, Bratt Göran, Schulman Sam, Bylund Håkan, Sandström Eric, Hypofibrinolytic State in HIV-1–Infected Patients Treated With Protease Inhibitor–Containing Highly Active Antiretroviral Therapy : , 10.1097/00042560-200204150-00003
  41. Larsen C, Prevalence and prognosis of electrocardiographic left ventricular hypertrophy, ST segment depression and negative T-wave. The Copenhagen City Heart Study, 10.1053/euhj.2001.2774
  42. Doser Nicole, Kübli Sandrine, Telenti Amalio, Marzolini Catia, Chave Jean-Philippe, Feihl François, Buclin Thierry, Pannatier André, Darioli Roger, Nicod Pascal, Waeber Bernard, Mooser Vincent, Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients : , 10.1097/00002030-200209270-00024
  43. Baldini Francesco, Giambenedetto Simona Di, Cingolani Antonella, Murri Rita, Ammassari Adriana, Luca Andrea De, Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study : , 10.1097/00002030-200007280-00025
  44. Libby Peter, Aikawa Masanori, Mechanisms of plaque stabilization with statins, 10.1016/s0002-9149(02)03267-8
  45. Aberg JA., J Int Assoc Physicians AIDS Care (Chic III), 2, S24 (2003)
  46. Kuulasmaa Kari, Tunstall-Pedoe Hugh, Dobson Annette, Fortmann Stephen, Sans Susana, Tolonen Hanna, Evans Alun, Ferrario Marco, Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations, 10.1016/s0140-6736(99)11180-2
  47. Menotti A, Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart, 10.1136/heart.84.3.238
  48. Dubé Michael P., Stein James H., Aberg Judith A., Fichtenbaum Carl J., Gerber John G., Tashima Karen T., Henry W. Keith, Currier Judith S., Sprecher Dennis, Glesby Marshall J., Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group, 10.1086/378131
Bibliographic reference Law, MG ; Friis-Moller, N. ; El-Sadr, WM ; Weber, R. ; Reiss, P. ; et. al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D : A : D Study. In: HIV Medicine, Vol. 7, no. 4, p. 218-230 (2006)
Permanent URL http://hdl.handle.net/2078.1/38567